Cardiolife’s AI technology is powering a new Holter analysis solution from Cardioline. MindBeat powered by Cardiolife combines advanced AI with Cardioline’s expertise in cardiac monitoring to help clinicians analyse long-duration Holter recordings more efficiently, while maintaining full clinical control.

Cardiolife’s AI-powered ECG interpretation software is now cleared for commercial use in Switzerland following CE certification under the EU Medical Device Regulation (MDR) and registration in SwissDamed, Switzerland’s national database for medical devices.

Cardiolife’s AI-powered ECG interpretation software has received regulatory approval for commercial use in the United Arab Emirates, enabling the company to bring its technology to healthcare providers across the UAE and marking another important step in its international expansion.

Cardiolife is a consortium partner in a Portuguese–EU research program under the COMPETE 2030 initiative, focused on developing advanced digital health solutions for cardiovascular care. The project has been granted EU funding and is currently well underway.

Cardiolife’s AI-powered ECG interpretation software has been included in the Australian Register of Therapeutic Goods (ARTG No. 524682), enabling the company to supply its technology in Australia and marking another step in its international growth.

We are proud to share that Cardiolife has been selected to join the June 2026 Mayo Clinic Platform_Accelerate cohort.

Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide.